Can a Wisconsin plant change the face of nuclear imaging?

Moly-99, the radioisotope that fuels nuclear imaging, isn't currently produced in the United States. But in Janesville, Wisconsin, Shine Medical Technologies is building a $100 million plant that could manufacture up to 50,000 does of imaging agent a week, a New York Times article reports.

If this plant in Wisconsin is built, that would make it the first construction project to pass through the muddy nuclear regulatory approval process since 1985.

However, many hurdles must be cleared before Janesville can begin building.

Another company seeking to take hold of the moly-99 supply chain, NorthStar Medical Radioisotopes, is in the same county as Shine Medical, and was awarded $50 million in federal grants to start building. And although Shine is backed by $25 million in federal support, it must raise more money if it wants to start producing the radioisotopes by its goal of 2020.

To read the entire story, check out the link below:

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.